Analyst picks & changes

Somatix Therapy Corp. (SOMA)

Jeffrey Casdin of Oppenheimer & Co. added the company to OpCo's Recommended List and rated it a "buy." One of SOMA's main assets, said Casdin, is probably the strongest patent estate in the field of gene therapy, covering the use of a number of different cell types, and a broad issued patent covering the use of genetically altered cells in the brain. The latter is one of the most attractive areas of intervention for gene therapy approaches, he said. ...